<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01368497</url>
  </required_header>
  <id_info>
    <org_study_id>DK082864 HBRN IT Peds Trial</org_study_id>
    <secondary_id>U01DK082916</secondary_id>
    <secondary_id>U01DK082864</secondary_id>
    <secondary_id>U01DK082874</secondary_id>
    <secondary_id>U01DK082944</secondary_id>
    <secondary_id>U01DK082843</secondary_id>
    <secondary_id>U01DK082871</secondary_id>
    <secondary_id>UL1TR000423</secondary_id>
    <secondary_id>UL1TR000004</secondary_id>
    <secondary_id>A-DK-3002-001</secondary_id>
    <nct_id>NCT01368497</nct_id>
  </id_info>
  <brief_title>Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection</brief_title>
  <official_title>Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of treatment using a
      combination of drugs (entecavir and pegylated interferon) in children ages 3-&lt;18 years old
      with immunotolerant chronic hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single arm treatment study was conducted by the pediatric centers within the National
      Institute of Diabetes Digestive and Kidney Diseases (NIDDK)-sponsored Hepatitis B Research
      Network (HBRN). Children age 3-&lt;18 years with immunotolerant chronic hepatitis B (CHB)
      infection who fulfilled the entry criteria received entecavir as monotherapy for 8 weeks and
      then combination therapy with entecavir and pegylated interferon by weekly subcutaneous
      injection until week 48. Children were to be followed for 48 weeks after discontinuation of
      therapy (week 96 for those who completed 48 weeks of treatment).

      Assessment was undertaken at baseline, weeks 4, 8, 10, 12, 14, &amp; 16, then every 4 weeks until
      week 48, and then 4, 8, 12, 24,36, and 48 weeks following treatment discontinuation
      corresponding to weeks 52, 56, 60, 72, 84 and 96 for those who received treatment for 48
      weeks. Blood work was drawn to measure markers of viral and liver disease status and for
      research biospecimen banking.

      Participants were to receive therapy until week 48 and enter 48 weeks of follow-up
      thereafter. Participants who experienced a sustained elevation of alanine aminotransferase
      (ALT) were eligible to receive treatment as recommended by their hepatologist and continued
      to complete the study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 23, 2016</completion_date>
  <primary_completion_date type="Actual">December 23, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss &amp; Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels ≤1,000 International Units (IU) Per Milliliter (mL)</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs) Per Person-Year</measure>
    <time_frame>From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)</time_frame>
    <description>The number of AEs includes both AEs and Serious Adverse Events (SAEs). The incidence is calculated as the number of AEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs) Per Person-Year</measure>
    <time_frame>From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)</time_frame>
    <description>The incidence is calculated as the number of SAEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Seroconversion</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBeAg Seroconversion</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBsAg Seroconversion</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBsAg Seroconversion</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Alanine Aminotransferase (ALT) ≤ 40 Units (U) Per Liter (L) for Males, ≤ 35 U/L for Females</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With ALT ≤ 40 U/L for Males, ≤ 35 U/L for Females</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBV DNA ≤1000 IU/mL</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBV DNA ≤1000 IU/mL</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBV DNA &lt; 20 IU/mL</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With HBV DNA &lt; 20 IU/mL</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Detectable Antiviral Drug-resistance HBV Mutations</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Measures: Z-scores Weight, Height, and Body Mass Index</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
    <description>A child's Z-score is the number of standard deviations that the child is from the average of children of the same sex and age from a reference population. The reference population is provided in the 2000 Centers for Disease Control and Prevention (CDC) growth charts. Positive Z scores mean the growth measure (weight, height, or body mass index) is above the average, negative Z scores mean the growth measure is below the average.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Measures: Z-scores Weight, Height, and Body Mass Index</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
    <description>A child's Z-score is the number of standard deviations that the child is from the average of children of the same sex and age from a reference population. The reference population is provided in the 2000 Centers for Disease Control and Prevention (CDC) growth charts. Positive Z scores mean the growth measure (weight, height, or body mass index) is above the average, negative Z scores mean the growth measure is below the average.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner Stages of Physical Growth</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
    <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Girls selected the picture closest to their self-perceived breast growth from among 5 stages of breast growth and boys did the same for testes, scrotum, and penis growth.
Boys: I-prepubertal; II-enlargement of scrotum and testes; III-enlargement of the penis and further growth of testes; IV- increased size of penis with growth in breadth and development of glans, testes, and scrotum larger, scrotum skin darker; V- adult genitalia.
Girls: I-prepubertal; II-breast bud stage with the elevation of breast and papilla and enlargement of the areola; III-further enlargement of breast and areola, no separation of their contour; IV-areola and papilla form a secondary mound above the level of the breast; V: mature adult stage.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner Stages of Physical Growth</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
    <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Girls selected the picture closest to their self-perceived breast growth from among 5 stages of breast growth and boys did the same for testes, scrotum, and penis growth.
Boys: I-prepubertal; II-enlargement of scrotum and testes; III-enlargement of the penis and further growth of testes; IV- increased size of penis with growth in breadth and development of glans, testes, and scrotum larger, scrotum skin darker; V- adult genitalia.
Girls: I-prepubertal; II-breast bud stage with the elevation of breast and papilla and enlargement of the areola; III-further enlargement of breast and areola, no separation of their contour; IV-areola and papilla form a secondary mound above the level of the breast; V: mature adult stage.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner Stages of Pubic Hair Growth</measure>
    <time_frame>End of treatment (up to 48 weeks)</time_frame>
    <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Participants selected the picture closest to their self-perceived pubic hair growth.
Boys and girls: I-prepubertal (no pubic hair at all); II-sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia; III: darker, coarser and more curled hair, spreading sparsely over junction of pubes; IV- hair adult in type, but covering smaller area than in adult; V-adult in type and quantity.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tanner Stages of Pubic Hair Growth</measure>
    <time_frame>End of follow-up (up to 96 weeks)</time_frame>
    <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Participants selected the picture closest to their self-perceived pubic hair growth.
Boys and girls: I-prepubertal (no pubic hair at all); II-sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia; III: darker, coarser and more curled hair, spreading sparsely over junction of pubes; IV- hair adult in type, but covering smaller area than in adult; V-adult in type and quantity.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Entecavir and peginterferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Entecavir for 8 weeks followed by 40 weeks of both entecavir and peginterferon</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir and peginterferon</intervention_name>
    <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).</description>
    <arm_group_label>Entecavir and peginterferon</arm_group_label>
    <other_name>PEGASYS, peginterferon alfa 2a, Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrolled in &amp; completed the baseline evaluation in NCT01263600 OR completed necessary
             components of NCT01263600 baseline evaluation by the end of the baseline visit.

          -  3 to &lt;18 years at time of randomization (day 0).

          -  Documented chronic Hepatitis B virus (HBV) infection as evidenced by detection of
             hepatitis B surface antigen (HBsAg) in serum for ≥ 24 weeks prior to baseline OR
             positive HBsAg and negative anti-Hepatitis B core (HBc) immunoglobulin (IgM) within 24
             weeks of baseline visit.

          -  Presence of hepatitis B e-antigen (HBeAg) in serum at the last screening visit within
             6 weeks of baseline visit.

          -  Serum HBV DNA level &gt;10^7 IU/mL on at least 2 occasions at least 12 weeks apart during
             the 52 weeks before baseline visit. The HBV DNA levels must be within 6 weeks of
             baseline visit.

          -  ALT ≤60 U/l in males or ≤40 U/l in females, measured on at least 2 occasions, at
             screening (within 6 weeks prior to baseline visit) &amp; at least 12 weeks prior to the
             screening visit &amp; within the 52 weeks prior to baseline visit.

          -  Compensated liver disease, with normal total bilirubin (except if Gilbert's syndrome),
             direct bilirubin ≤0.5 mg/dL, International Normalized Ratio (INR) ≤1.5, and serum
             albumin ≥3.5 g/dL.

          -  Creatinine clearance 90 ml/min.

          -  Absence of hepatocellular carcinoma on liver ultrasound in the past 48 weeks.

        Exclusion criteria:

          -  Presence of infection with Hepatitis C virus (HCV)-RNA or anti-HCV, anti-Hepatitis D
             virus (HDV), or HIV at screening.

          -  Presence of another cause of liver disease or hepatocellular cancer (HCC) (serum
             alpha-fetoprotein &gt;50ng /ml).

          -  Evidence of decompensated liver disease (Childs B-C).

          -  History or other evidence of a medical condition associated with chronic liver disease
             (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin
             exposures).

          -  Females who are pregnant or breastfeeding.

          -  Adolescent females unwilling or unable to use an acceptable method of contraception if
             sexually active during the treatment period.

          -  Children currently breastfeeding while their mother is taking lamivudine, or those who
             were exposed to lamivudine for ≥24 weeks via maternal lamivudine treatment during
             pregnancy and/or while breastfeeding.

          -  Previous liver or other organ transplantation including engrafted bone marrow
             transplant.

          -  Hematological abnormalities during the screening period that contraindicate full
             dosing with study drugs, e.g absolute neutrophil count &lt; 1.5 x 10^9 cells/L or
             platelet count &lt; 120 x 10^9 cells/L.

          -  Known allergy to study drugs; peginterferon alfa-2a or entecavir.

          -  Treatment with systemic acyclovir or famciclovir within the previous 6 months.

          -  Need for ongoing use of any antivirals with activity against HBV during the course of
             the study or history of receiving treatment for HBV.

          -  Any use of illegal drugs OR use of alcoholic beverages which in the opinion of a study
             physician is sufficient to prevent adequate compliance with study procedures or
             increase the risk of pancreatitis or hepatotoxicity.

          -  History of immunologically mediated disease (e.g. inflammatory bowel disease,
             idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune haemolytic
             anemia, scleroderma, severe psoriasis, rheumatoid arthritis).

          -  History or other evidence of bleeding from esophageal varices or consistent with
             decompensated liver disease.

          -  History or other evidence of chronic pulmonary disease associated with functional
             limitation.

          -  History of significant cardiovascular diseases.

          -  History of a severe seizure disorder or current anticonvulsant use.

          -  History or other evidence of severe retinopathy.

          -  History of thyroid disease poorly controlled on prescribed medications. Participants
             with elevated thyroid stimulating hormone concentrations with elevation of antibodies
             to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded.

          -  Concomitant use or use during ≤ 6 months prior to the first dose of study drug of
             anti-neoplastic, immunosuppressive, nephrotoxic or hepatotoxic medication, methadone,
             theophylline or medications that may affect renal excretion or hepatic metabolism are
             not permitted.

          -  Concomitant use of complementary or alternative medications purported to have
             antiviral activity.

          -  A participant may not be co-enrolled in another clinical trial where an
             investigational drug is administered.

          -  Any other condition or situation that in the opinion of a study physician would make
             the participant unsuitable for enrollment or could interfere with the participant
             participating in and completing the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Averell Sherker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ed Doo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Schwarz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>m5g1x8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hepbnet.org/</url>
    <description>Click here for more information about the Hepatitis B Research Network</description>
  </link>
  <link>
    <url>http://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm</url>
    <description>Calculates Z-scores for a child's sex and age for BMI, weight, and height</description>
  </link>
  <reference>
    <citation>Morris NM, Udry JR. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc. 1980 Jun;9(3):271-80. doi: 10.1007/BF02088471.</citation>
    <PMID>24318082</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 6, 2011</study_first_submitted>
  <study_first_submitted_qc>June 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2011</study_first_posted>
  <results_first_submitted>March 13, 2018</results_first_submitted>
  <results_first_submitted_qc>June 29, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 3, 2018</results_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All data will be sent to the NIDDK-supported data repository.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>At completion of HBRN project. Length of availability determined by NIDDK data repository.</ipd_time_frame>
    <ipd_access_criteria>Per NIDDK-supported data repository.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 19, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT01368497/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sixty children were enrolled at 7 pediatric clinical sites in the United States and Canada between 9/20/2012 and 12/30/2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Entecavir and Peginterferon</title>
          <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>End of Treatment</title>
              <participants_list>
                <participants group_id="P1" count="60">Five discontinued study drugs early and completed the follow-up period per protocol.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entecavir and Peginterferon</title>
          <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" lower_limit="3.4" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV DNA</title>
          <units>log10 IU/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" lower_limit="7.5" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss &amp; Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels ≤1,000 International Units (IU) Per Milliliter (mL)</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss &amp; Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels ≤1,000 International Units (IU) Per Milliliter (mL)</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events (AEs) Per Person-Year</title>
        <description>The number of AEs includes both AEs and Serious Adverse Events (SAEs). The incidence is calculated as the number of AEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
        <time_frame>From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events (AEs) Per Person-Year</title>
          <description>The number of AEs includes both AEs and Serious Adverse Events (SAEs). The incidence is calculated as the number of AEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
          <units>AEs per person-year of observation</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of treatment (Up to 48 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.88" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of follow-up (Up to 96 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" lower_limit="0.56" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Serious Adverse Events (SAEs) Per Person-Year</title>
        <description>The incidence is calculated as the number of SAEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
        <time_frame>From first treatment to the end of treatment (up to 48 weeks) and the end of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Serious Adverse Events (SAEs) Per Person-Year</title>
          <description>The incidence is calculated as the number of SAEs divided by the number of person-years of observation, which is the sum, across all participants, of the number of years between the start of treatment and the end of treatment, or the end of follow-up, respectively.</description>
          <units>SAEs per person-year of observation</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of treatment (Up to 48 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">95% Confidence Interval (CI) around 0 not calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of follow-up (Up to 96 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="0.00" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".050" lower_limit=".010" upper_limit=".139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBeAg Seroconversion</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBeAg Seroconversion</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBeAg Seroconversion</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBeAg Seroconversion</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBsAg Seroconversion</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBsAg Seroconversion</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBsAg Seroconversion</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBsAg Seroconversion</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Alanine Aminotransferase (ALT) ≤ 40 Units (U) Per Liter (L) for Males, ≤ 35 U/L for Females</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Alanine Aminotransferase (ALT) ≤ 40 Units (U) Per Liter (L) for Males, ≤ 35 U/L for Females</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".350" lower_limit=".231" upper_limit=".484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With ALT ≤ 40 U/L for Males, ≤ 35 U/L for Females</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With ALT ≤ 40 U/L for Males, ≤ 35 U/L for Females</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".650" lower_limit=".516" upper_limit=".769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBV DNA ≤1000 IU/mL</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBV DNA ≤1000 IU/mL</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".750" lower_limit=".621" upper_limit=".853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBV DNA ≤1000 IU/mL</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBV DNA ≤1000 IU/mL</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBV DNA &lt; 20 IU/mL</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBV DNA &lt; 20 IU/mL</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".233" lower_limit=".134" upper_limit=".360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With HBV DNA &lt; 20 IU/mL</title>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With HBV DNA &lt; 20 IU/mL</title>
          <units>Proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".033" lower_limit=".004" upper_limit=".115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Detectable Antiviral Drug-resistance HBV Mutations</title>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <posting_date>08/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Measures: Z-scores Weight, Height, and Body Mass Index</title>
        <description>A child's Z-score is the number of standard deviations that the child is from the average of children of the same sex and age from a reference population. The reference population is provided in the 2000 Centers for Disease Control and Prevention (CDC) growth charts. Positive Z scores mean the growth measure (weight, height, or body mass index) is above the average, negative Z scores mean the growth measure is below the average.</description>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Measures: Z-scores Weight, Height, and Body Mass Index</title>
          <description>A child's Z-score is the number of standard deviations that the child is from the average of children of the same sex and age from a reference population. The reference population is provided in the 2000 Centers for Disease Control and Prevention (CDC) growth charts. Positive Z scores mean the growth measure (weight, height, or body mass index) is above the average, negative Z scores mean the growth measure is below the average.</description>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Z-score weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" lower_limit="-0.94" upper_limit="-0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Z-score height</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" lower_limit="-0.78" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Z-score BMI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" lower_limit="-0.82" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Measures: Z-scores Weight, Height, and Body Mass Index</title>
        <description>A child's Z-score is the number of standard deviations that the child is from the average of children of the same sex and age from a reference population. The reference population is provided in the 2000 Centers for Disease Control and Prevention (CDC) growth charts. Positive Z scores mean the growth measure (weight, height, or body mass index) is above the average, negative Z scores mean the growth measure is below the average.</description>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Measures: Z-scores Weight, Height, and Body Mass Index</title>
          <description>A child's Z-score is the number of standard deviations that the child is from the average of children of the same sex and age from a reference population. The reference population is provided in the 2000 Centers for Disease Control and Prevention (CDC) growth charts. Positive Z scores mean the growth measure (weight, height, or body mass index) is above the average, negative Z scores mean the growth measure is below the average.</description>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Z-score weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" lower_limit="-0.81" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Z-score height</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" lower_limit="-0.88" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Z-score BMI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" lower_limit="-0.54" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tanner Stages of Physical Growth</title>
        <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Girls selected the picture closest to their self-perceived breast growth from among 5 stages of breast growth and boys did the same for testes, scrotum, and penis growth.
Boys: I-prepubertal; II-enlargement of scrotum and testes; III-enlargement of the penis and further growth of testes; IV- increased size of penis with growth in breadth and development of glans, testes, and scrotum larger, scrotum skin darker; V- adult genitalia.
Girls: I-prepubertal; II-breast bud stage with the elevation of breast and papilla and enlargement of the areola; III-further enlargement of breast and areola, no separation of their contour; IV-areola and papilla form a secondary mound above the level of the breast; V: mature adult stage.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tanner Stages of Physical Growth</title>
          <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Girls selected the picture closest to their self-perceived breast growth from among 5 stages of breast growth and boys did the same for testes, scrotum, and penis growth.
Boys: I-prepubertal; II-enlargement of scrotum and testes; III-enlargement of the penis and further growth of testes; IV- increased size of penis with growth in breadth and development of glans, testes, and scrotum larger, scrotum skin darker; V- adult genitalia.
Girls: I-prepubertal; II-breast bud stage with the elevation of breast and papilla and enlargement of the areola; III-further enlargement of breast and areola, no separation of their contour; IV-areola and papilla form a secondary mound above the level of the breast; V: mature adult stage.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tanner Stages of Physical Growth</title>
        <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Girls selected the picture closest to their self-perceived breast growth from among 5 stages of breast growth and boys did the same for testes, scrotum, and penis growth.
Boys: I-prepubertal; II-enlargement of scrotum and testes; III-enlargement of the penis and further growth of testes; IV- increased size of penis with growth in breadth and development of glans, testes, and scrotum larger, scrotum skin darker; V- adult genitalia.
Girls: I-prepubertal; II-breast bud stage with the elevation of breast and papilla and enlargement of the areola; III-further enlargement of breast and areola, no separation of their contour; IV-areola and papilla form a secondary mound above the level of the breast; V: mature adult stage.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tanner Stages of Physical Growth</title>
          <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Girls selected the picture closest to their self-perceived breast growth from among 5 stages of breast growth and boys did the same for testes, scrotum, and penis growth.
Boys: I-prepubertal; II-enlargement of scrotum and testes; III-enlargement of the penis and further growth of testes; IV- increased size of penis with growth in breadth and development of glans, testes, and scrotum larger, scrotum skin darker; V- adult genitalia.
Girls: I-prepubertal; II-breast bud stage with the elevation of breast and papilla and enlargement of the areola; III-further enlargement of breast and areola, no separation of their contour; IV-areola and papilla form a secondary mound above the level of the breast; V: mature adult stage.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tanner Stages of Pubic Hair Growth</title>
        <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Participants selected the picture closest to their self-perceived pubic hair growth.
Boys and girls: I-prepubertal (no pubic hair at all); II-sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia; III: darker, coarser and more curled hair, spreading sparsely over junction of pubes; IV- hair adult in type, but covering smaller area than in adult; V-adult in type and quantity.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
        <time_frame>End of treatment (up to 48 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tanner Stages of Pubic Hair Growth</title>
          <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Participants selected the picture closest to their self-perceived pubic hair growth.
Boys and girls: I-prepubertal (no pubic hair at all); II-sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia; III: darker, coarser and more curled hair, spreading sparsely over junction of pubes; IV- hair adult in type, but covering smaller area than in adult; V-adult in type and quantity.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tanner Stages of Pubic Hair Growth</title>
        <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Participants selected the picture closest to their self-perceived pubic hair growth.
Boys and girls: I-prepubertal (no pubic hair at all); II-sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia; III: darker, coarser and more curled hair, spreading sparsely over junction of pubes; IV- hair adult in type, but covering smaller area than in adult; V-adult in type and quantity.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
        <time_frame>End of follow-up (up to 96 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Entecavir and Peginterferon</title>
            <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant’s body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tanner Stages of Pubic Hair Growth</title>
          <description>The Tanner Stage questionnaire is only completed by participants 8 years of age and older. The copyrighted form includes pictures and descriptions. Participants selected the picture closest to their self-perceived pubic hair growth.
Boys and girls: I-prepubertal (no pubic hair at all); II-sparse growth of long, slightly pigmented hair, straight or curled, at base of penis or along labia; III: darker, coarser and more curled hair, spreading sparsely over junction of pubes; IV- hair adult in type, but covering smaller area than in adult; V-adult in type and quantity.
There is no &quot;better&quot; or &quot;worse&quot; outcome. They are self-assessed descriptive measures of physical growth.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study entry (consent) to the end of follow-up (48 weeks following the end of treatment).</time_frame>
      <desc>Expected symptoms/signs or common side effects of study meds need not be reported (these are Adverse Effects). These are a guide for recording adverse events, which are at the discretion of the investigator.
Symptom or event requiring discontinuation of study medication.
New symptom or event requiring a written prescription for treatment.
New symptom or event resulting in a referral to another provider.
Grade 3 or 4 event per the NCI Common Toxicity Criteria.</desc>
      <group_list>
        <group group_id="E1">
          <title>Entecavir and Peginterferon</title>
          <description>Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 μg/1.73m^2 subcutaneously times the participant's body surface area once weekly during weeks 9-48 of treatment. After treatment discontinuation, follow-up off treatment for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Small splenic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Low absolute neutrophil count</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Low absolute neutrophil count and platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope Episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid in left ear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid-stimulating hormone (TSH) elevation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Blurry vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Decreased visual acuity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upset stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Elective extraction of four primary teeth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Nauseous and achy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Mild nose bleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT or AST elevation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Total bilirubin elevation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral periocular dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Bilateral rash and swelling of feet</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Strep throat</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Infection from tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Keratitis and uveitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Sore throat and fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Creatine kinase elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ptosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Febrile seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Short temper or slight agitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Occult blood in urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual cramping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Skin lesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Abscess gum from tooth extraction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Belle</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-624-3758</phone>
      <email>belle@edc.pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

